BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan (sapropterin dihydrochloride) for the treatment of hyperphenylalaninemia in phenylketonuria or BH4 deficient patients from the European Commission.
The details can be read here.
No comments:
Post a Comment